Low dose Rituximab for pre-emptive treatment of Epstein Barr virus reactivation after allogenic hematopoietic stem cell transplantation

B. Delapierre (1, 2) , O. Reman (3) , J. Dina (4, 5) , C. Breuil (6) , M. Bellal (1, 2) , H. Johnson-Ansah (1, 2) , C. Gac (1, 2) , G. Damaj (1, 2) , S. Chantepie (2)

1 UNICAEN - Université de Caen Normandie
2 Hôpital Côte de Nacre [CHU Caen]
3 Laboratoire d'Hématologie Biologique [CHU Caen]
4 Service de Virologie [CHU Caen]
5 GRAM 2.0 - Groupe de Recherche sur l'Adaptation Microbienne
6 Service de Pharmacie [CHU Caen]

Domaines: Virologie; Bactériologie; Microbiologie et Parasitologie

B. Delapierre, O. Reman, J. Dina, C. Breuil, M. Bellal, et al.. Low dose Rituximab for pre-emptive treatment of Epstein Barr virus reactivation after allogenic hematopoietic stem cell transplantation. Current Research in Translational Medicine, 2019, ⟨10.1016/j.retram.2019.03.001⟩. ⟨hal-02153833⟩